NTRB
Price
$6.57
Change
+$0.27 (+4.29%)
Updated
Aug 15 closing price
Capitalization
73.13M
45 days until earnings call
REPL
Price
$5.56
Change
+$0.21 (+3.93%)
Updated
Aug 15 closing price
Capitalization
433.99M
93 days until earnings call
Interact to see
Advertisement

NTRB vs REPL

Header iconNTRB vs REPL Comparison
Open Charts NTRB vs REPLBanner chart's image
Nutriband
Price$6.57
Change+$0.27 (+4.29%)
Volume$38.25K
Capitalization73.13M
Replimune Group
Price$5.56
Change+$0.21 (+3.93%)
Volume$5.77M
Capitalization433.99M
NTRB vs REPL Comparison Chart in %
Loading...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTRB vs. REPL commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRB is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (NTRB: $6.57 vs. REPL: $5.56)
Brand notoriety: NTRB and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTRB: 26% vs. REPL: 51%
Market capitalization -- NTRB: $73.13M vs. REPL: $433.99M
NTRB [@Biotechnology] is valued at $73.13M. REPL’s [@Biotechnology] market capitalization is $433.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRB’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • NTRB’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRB’s TA Score shows that 4 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • NTRB’s TA Score: 4 bullish, 5 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than NTRB.

Price Growth

NTRB (@Biotechnology) experienced а -8.37% price change this week, while REPL (@Biotechnology) price change was +5.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

NTRB is expected to report earnings on Oct 01, 2025.

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($434M) has a higher market cap than NTRB($73.1M). NTRB YTD gains are higher at: 39.490 vs. REPL (-54.088). NTRB has higher annual earnings (EBITDA): -9.68M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. NTRB (2.96M). NTRB has less debt than REPL: NTRB (282K) vs REPL (76.2M). NTRB has higher revenues than REPL: NTRB (2.4M) vs REPL (0).
NTRBREPLNTRB / REPL
Capitalization73.1M434M17%
EBITDA-9.68M-235.43M4%
Gain YTD39.490-54.088-73%
P/E RatioN/AN/A-
Revenue2.4M0-
Total Cash2.96M484M1%
Total Debt282K76.2M0%
FUNDAMENTALS RATINGS
NTRB vs REPL: Fundamental Ratings
NTRB
REPL
OUTLOOK RATING
1..100
9084
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6397
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for NTRB (70) in the null industry. This means that REPL’s stock grew somewhat faster than NTRB’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that REPL’s stock grew similarly to NTRB’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as NTRB (99) in the null industry. This means that REPL’s stock grew similarly to NTRB’s over the last 12 months.

NTRB's Price Growth Rating (63) in the null industry is somewhat better than the same rating for REPL (97) in the Biotechnology industry. This means that NTRB’s stock grew somewhat faster than REPL’s over the last 12 months.

NTRB's P/E Growth Rating (100) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRBREPL
RSI
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
78%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NLST0.820.03
+4.14%
Netlist, Inc.
HRGN1.54N/A
+0.19%
Harvard Apparatus Regenerative Technology Inc.
KNBWF13.64N/A
N/A
Kirin Holdings Co., Ltd.
IWTNF10.50N/A
N/A
IWATANI CORP.
GTIC0.08N/A
N/A
GreenTech Innovations, Inc.

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and ABSI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and ABSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
+4.29%
ABSI - NTRB
29%
Poorly correlated
-2.33%
STOK - NTRB
27%
Poorly correlated
+6.06%
NTLA - NTRB
26%
Poorly correlated
+0.83%
REPL - NTRB
25%
Poorly correlated
+3.93%
GLMD - NTRB
25%
Poorly correlated
-2.70%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+3.93%
IMNN - REPL
56%
Loosely correlated
-3.03%
SNDX - REPL
49%
Loosely correlated
+6.86%
KYMR - REPL
46%
Loosely correlated
+2.60%
ERAS - REPL
44%
Loosely correlated
+4.46%
BEAM - REPL
43%
Loosely correlated
+1.08%
More